Core Insights - Apyx Medical Corporation reported a record total revenue of $19.2 million for Q4 2025, a 34.7% increase from $14.2 million in Q4 2024, driven by strong demand for the AYON Body Contouring System [4][5][7] - The company anticipates total revenue for FY2026 to be between $57.5 million and $58.5 million, with Surgical Aesthetics revenue projected to be in the range of $53.0 million to $54.0 million [4][20] Financial Performance - Surgical Aesthetics revenue for Q4 2025 was $16.7 million, up 38.1% from $12.1 million in Q4 2024, primarily due to nearly 50% growth in U.S. sales [5][7] - OEM revenue for Q4 2025 was approximately $2.5 million, reflecting a 15.6% increase from $2.1 million in Q4 2024 [5][6] - For the full year 2025, total revenue increased by 9.9% to $52.8 million compared to $48.1 million in 2024 [12][16] Profitability Metrics - Gross profit for Q4 2025 rose to $12.0 million, with a gross margin of 62.6%, slightly down from 63.0% in the prior year [8] - Adjusted EBITDA for Q4 2025 was $0.7 million, a significant improvement from an adjusted EBITDA loss of $2.2 million in Q4 2024 [11][34] - The net loss attributable to stockholders for Q4 2025 was $1.3 million, compared to a net loss of $4.6 million in Q4 2024 [10][34] Operating Expenses - Operating expenses remained flat at $12.0 million for Q4 2025, with minor fluctuations in various expense categories [9] - For the full year 2025, operating expenses decreased to $39.5 million from $48.2 million in 2024, driven by reductions in salaries, administrative, and research expenses [15] Market Position and Product Development - The AYON Body Contouring System, launched in September 2025, is expected to drive significant growth as awareness increases [3][4] - The company submitted a new 510(k) premarket notification to the FDA for AYON's label expansion to include power liposuction, with potential clearance anticipated in mid-2026 [5][21]

Core Viewpoint - Apyx Medical Corporation will participate in The Citizens Life Sciences Conference on March 11, 2026, showcasing its leadership in surgical aesthetics and innovative products [1][2]. Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering products such as Renuvion and the AYON Body Contouring System™ [3]. - The company utilizes Helium Plasma Platform Technology, which provides controlled heat to tissue, enhancing surgical outcomes [3]. - Renuvion and J-Plasma are supported by over 90 clinical documents, demonstrating their effectiveness in cosmetic and hospital surgical markets [3]. - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, empowering surgeons with a comprehensive treatment platform [3]. - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3].

Core Viewpoint - Apyx Medical Corporation reported preliminary revenue results for Q4 and full year 2025, highlighting strong growth driven by the commercial launch of the AYON Body Contouring System and increased demand in the surgical aesthetics market [1][4]. Preliminary Fourth Quarter 2025 Revenue Summary - Total revenue for Q4 2025 is expected to be in the range of approximately $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year [7]. - Surgical Aesthetics revenue for Q4 2025 is expected to be in the range of approximately $16.6 to $16.8 million, reflecting an increase of approximately 38% year-over-year [7]. - OEM revenue for Q4 2025 is expected to be approximately $2.4 million, indicating an increase of approximately 13% year-over-year [7]. Preliminary Full Year 2025 Revenue Summary - Total revenue for the full year 2025 is expected to be in the range of approximately $52.7 to $52.9 million, representing an increase of approximately 10% year-over-year [7]. - Surgical Aesthetics revenue for the full year 2025 is expected to be in the range of approximately $45.2 to $45.4 million, showing an increase of approximately 17% year-over-year [7]. - OEM revenue for the full year 2025 is expected to be approximately $7.5 million, reflecting a decrease of 21% year-over-year [7]. Industry Context - The commercial launch of AYON has generated immediate momentum, contributing to a strong fourth quarter performance, with a noted increase in aesthetic surgical procedures in the U.S. driven by the adoption of GLP-1 therapies leading to significant patient weight loss [4]. - The company is positioned to capitalize on the positive industry momentum in the surgical aesthetics market [4]. Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion® and the AYON Body Contouring System™ [5]. - The AYON Body Contouring System is an FDA-cleared, surgeon-designed platform that integrates various capabilities for comprehensive body contouring treatments [5]. - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical documents, showcasing the company's commitment to innovation in the cosmetic surgery market [5].

Core Insights - Apyx Medical Corporation has received regulatory approval for the Apyx One console and plans to launch commercial sales in South Korea, with initial orders expected in Q4 2025 [1][3] - The Apyx One console features a 3-in-1 energy system that allows for advanced surgical procedures, including Renuvion technology, and is designed for ease of use with adaptive touch screens and energy quantification [2] - The cosmetic surgery market in South Korea is projected to grow from $1.7 billion in 2024 to over $3.9 billion by 2033, indicating a significant opportunity for Apyx Medical's body contouring technology [3] Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion and the AYON Body Contouring System, which provide controlled heat to tissue for surgical procedures [4] - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, enhancing the versatility and precision of body contouring treatments [4]

Core Insights - Apyx Medical Corporation reported a 19% increase in Surgical Aesthetics revenue for Q3 2025, driven by the successful commercialization of the AYON Body Contouring System [3][9] - The company anticipates further growth in sales following the pending FDA clearance for the AYON's label expansion to include power liposuction [4][7] - Total revenue for Q3 2025 reached $12.9 million, a 12.1% increase compared to $11.5 million in the same period last year [7][9] Financial Performance - Surgical Aesthetics revenue for Q3 2025 was $11.1 million, up from $9.3 million in Q3 2024, reflecting a 19% increase [9][10] - OEM revenue decreased by 18% to approximately $1.8 million in Q3 2025 compared to $2.2 million in Q3 2024 [7][9] - Gross profit for Q3 2025 increased to $8.3 million, with a gross margin of 64.4%, up from 60.5% in the prior year [10][12] Operating Expenses and Losses - Operating expenses decreased by $1.5 million to $9.1 million in Q3 2025 compared to $10.6 million in Q3 2024 [11] - Net loss attributable to stockholders was $2.0 million in Q3 2025, an improvement from a net loss of $4.7 million in Q3 2024 [12][24] - Adjusted EBITDA loss decreased significantly to $0.1 million for Q3 2025, compared to $2.4 million for the same period in 2024 [13][31] Future Outlook - The company raised its total revenue guidance for FY2025 to a range of $50.5 million to $52.5 million, up from the previous guidance of $50.0 million to $52.0 million [6][20] - Surgical Aesthetics revenue is expected to be between $43.0 million and $45.0 million for FY2025, compared to approximately $38.6 million reported for FY2024 [20] - The company plans to continue expanding the user base for AYON, which is expected to drive growth in single-use handpiece sales [4][6]

Apyx Medical (NasdaqGS:APYX) Conference Call Summary Company Overview - **Company**: Apyx Medical Corporation - **Event Date**: October 14, 2025 - **Key Product**: Apyx One Console, a body contouring system Industry Insights - **Market Context**: The surgical aesthetics market is evolving, particularly due to the rise of GLP-1 therapies for weight loss, leading to increased demand for body contouring solutions among post-weight loss patients [4][6] - **Market Size**: GLP-1 therapies are projected to exceed $100 billion by 2030, with 44% of users spending between $2,000 and $5,000 on aesthetic procedures, a 25% increase in spending [6] - **Patient Demographics**: 63% of GLP-1 users are new to aesthetics post-weight loss, indicating a growing patient population for plastic surgeons [6] Product Launch and Performance - **Product Launch**: Apyx One Console received approval in May 2025 and has undergone a successful soft launch with key surgeons across the U.S. [5][4] - **Sales Update**: Commercial sales began in September 2025, with ongoing sales in Q4 2025. A 510(k) submission for the power-assisted handpiece is expected to receive clearance in Q1 2026 [5][6] - **Technological Advancements**: The Apyx One Console integrates multiple technologies, including ultrasound-assisted liposuction and Renuvion for skin tightening, designed based on feedback from leading plastic surgeons [10][12] Clinical Insights - **Surgical Trends**: There has been a decline in liposuction procedures by 10.7%, while surgical lifts have increased by over 20%, reflecting the need for more complex surgical interventions for patients with lax skin [7][8] - **Patient Concerns**: 72% of GLP-1 users report loose skin as their primary concern, with 57% seeking treatment within six months post-weight loss [9] Feedback and Reception - **Surgeon Feedback**: Surgeons have expressed high satisfaction with the Apyx One Console, describing it as revolutionary and comparing it to luxury vehicles like Ferraris and Lamborghinis [13][14] - **Clinical Efficiency**: The integration of technologies in the Apyx One Console has led to improved surgical efficiency, with reduced procedure times and enhanced patient outcomes [32][51] Future Outlook - **Market Positioning**: Apyx Medical is well-positioned to capture growth in the surgical aesthetics market, particularly among post-weight loss patients seeking body contouring solutions [6][4] - **Anticipated Developments**: The upcoming launch of the power-assisted handpiece is expected to further enhance the capabilities of the Apyx One Console, attracting more surgeons and patients [65][66] Additional Insights - **Patient Experience**: The Apyx One Console aims to simplify the surgical process, reducing the need for multiple devices and improving the overall patient experience [21][22] - **Technological Trust**: Surgeons have shown a willingness to adopt the Apyx One Console based on the company's commitment to evidence-based medicine and the collaborative development process involving top surgeons [66][68] This summary encapsulates the key points discussed during the Apyx Medical conference call, highlighting the company's strategic positioning, product innovations, and the evolving landscape of the surgical aesthetics market.